A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 19 Jul 2011 Planned End Date changed from 1 Oct 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 07 May 2010 New trial record